EP4274894A2 - Prime-editor-varianten, konstrukte und verfahren zur verbesserung der prime-editierungseffizienz und -präzision - Google Patents
Prime-editor-varianten, konstrukte und verfahren zur verbesserung der prime-editierungseffizienz und -präzisionInfo
- Publication number
- EP4274894A2 EP4274894A2 EP22702103.7A EP22702103A EP4274894A2 EP 4274894 A2 EP4274894 A2 EP 4274894A2 EP 22702103 A EP22702103 A EP 22702103A EP 4274894 A2 EP4274894 A2 EP 4274894A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- fold
- seq
- dna
- amino acid
- basepair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 252
- 230000002708 enhancing effect Effects 0.000 title description 2
- 108020004414 DNA Proteins 0.000 claims abstract description 301
- 230000033607 mismatch repair Effects 0.000 claims abstract description 270
- 239000003112 inhibitor Substances 0.000 claims abstract description 207
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 204
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 186
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 186
- 230000037361 pathway Effects 0.000 claims abstract description 124
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 104
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 104
- 239000013598 vector Substances 0.000 claims abstract description 98
- 239000000203 mixture Substances 0.000 claims abstract description 89
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 78
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 78
- 239000002157 polynucleotide Substances 0.000 claims abstract description 78
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 62
- 230000004048 modification Effects 0.000 claims abstract description 56
- 238000012986 modification Methods 0.000 claims abstract description 56
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 40
- 230000001965 increasing effect Effects 0.000 claims abstract description 29
- 239000002773 nucleotide Substances 0.000 claims description 261
- 125000003729 nucleotide group Chemical group 0.000 claims description 261
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims description 252
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims description 252
- 108090000623 proteins and genes Proteins 0.000 claims description 234
- 108091033409 CRISPR Proteins 0.000 claims description 228
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 215
- 210000004027 cell Anatomy 0.000 claims description 172
- 102000004169 proteins and genes Human genes 0.000 claims description 155
- 238000012217 deletion Methods 0.000 claims description 121
- 230000037430 deletion Effects 0.000 claims description 121
- 108020005004 Guide RNA Proteins 0.000 claims description 116
- 230000000694 effects Effects 0.000 claims description 109
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 101
- 230000006820 DNA synthesis Effects 0.000 claims description 90
- 150000001413 amino acids Chemical class 0.000 claims description 85
- 238000003780 insertion Methods 0.000 claims description 81
- 230000037431 insertion Effects 0.000 claims description 81
- 238000006467 substitution reaction Methods 0.000 claims description 79
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 63
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 63
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
- 230000027455 binding Effects 0.000 claims description 55
- 101710163270 Nuclease Proteins 0.000 claims description 53
- 108020004459 Small interfering RNA Proteins 0.000 claims description 50
- 230000037432 silent mutation Effects 0.000 claims description 47
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims description 45
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 claims description 45
- 108050006400 Cyclin Proteins 0.000 claims description 44
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 44
- 230000035772 mutation Effects 0.000 claims description 44
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims description 43
- 102100031780 Endonuclease Human genes 0.000 claims description 43
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims description 43
- 102000010645 MutS Proteins Human genes 0.000 claims description 43
- 108010038272 MutS Proteins Proteins 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 43
- 102200051832 rs12513296 Human genes 0.000 claims description 43
- 239000004055 small Interfering RNA Substances 0.000 claims description 43
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims description 41
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims description 41
- 229910015837 MSH2 Inorganic materials 0.000 claims description 41
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 32
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 31
- 102100029075 Exonuclease 1 Human genes 0.000 claims description 31
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 30
- 108020004999 messenger RNA Proteins 0.000 claims description 29
- 125000006850 spacer group Chemical group 0.000 claims description 29
- 238000012937 correction Methods 0.000 claims description 28
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 27
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 26
- 101000727836 Homo sapiens Reduced folate transporter Proteins 0.000 claims description 25
- 241000713666 Lentivirus Species 0.000 claims description 25
- 102100029753 Reduced folate transporter Human genes 0.000 claims description 25
- -1 POLį Proteins 0.000 claims description 24
- 150000003384 small molecules Chemical group 0.000 claims description 24
- 102100028849 DNA mismatch repair protein Mlh3 Human genes 0.000 claims description 23
- 101000577867 Homo sapiens DNA mismatch repair protein Mlh3 Proteins 0.000 claims description 23
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 claims description 23
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 230000001419 dependent effect Effects 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 230000003247 decreasing effect Effects 0.000 claims description 18
- 108020004705 Codon Proteins 0.000 claims description 17
- 230000006870 function Effects 0.000 claims description 17
- 238000009434 installation Methods 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 230000007704 transition Effects 0.000 claims description 17
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108010042407 Endonucleases Proteins 0.000 claims description 15
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 14
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 14
- 108700004991 Cas12a Proteins 0.000 claims description 14
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 14
- 101710096438 DNA-binding protein Proteins 0.000 claims description 14
- 108700011259 MicroRNAs Proteins 0.000 claims description 13
- 239000002679 microRNA Substances 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 238000011144 upstream manufacturing Methods 0.000 claims description 12
- 102000008682 Argonaute Proteins Human genes 0.000 claims description 11
- 108010088141 Argonaute Proteins Proteins 0.000 claims description 11
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 11
- 230000004075 alteration Effects 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000007056 sickle cell anemia Diseases 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 230000003234 polygenic effect Effects 0.000 claims description 8
- 239000013607 AAV vector Substances 0.000 claims description 7
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 7
- 208000027472 Galactosemias Diseases 0.000 claims description 7
- 208000018565 Hemochromatosis Diseases 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 208000030162 Maple syrup disease Diseases 0.000 claims description 7
- 208000001826 Marfan syndrome Diseases 0.000 claims description 7
- 208000024556 Mendelian disease Diseases 0.000 claims description 7
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 7
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 7
- 208000001052 Pachyonychia Congenita Diseases 0.000 claims description 7
- 201000011252 Phenylketonuria Diseases 0.000 claims description 7
- 208000024777 Prion disease Diseases 0.000 claims description 7
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 claims description 7
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 7
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 7
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 208000024393 maple syrup urine disease Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- 108091006112 ATPases Proteins 0.000 claims description 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 5
- 108091092724 Noncoding DNA Proteins 0.000 claims description 4
- 102000006382 Ribonucleases Human genes 0.000 claims description 4
- 108010083644 Ribonucleases Proteins 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 102220592349 Mismatch repair endonuclease PMS2_E41A_mutation Human genes 0.000 claims description 3
- 102220086654 rs864622439 Human genes 0.000 claims description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 claims 5
- 101000918264 Homo sapiens Exonuclease 1 Proteins 0.000 claims 5
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 102100036512 7-dehydrocholesterol reductase Human genes 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 41
- 230000001976 improved effect Effects 0.000 abstract description 25
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 117
- 102100034343 Integrase Human genes 0.000 description 56
- 101150104383 ALOX5AP gene Proteins 0.000 description 40
- 101100236114 Mus musculus Lrrfip1 gene Proteins 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 36
- 238000010446 CRISPR interference Methods 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 35
- 230000000903 blocking effect Effects 0.000 description 32
- 230000000415 inactivating effect Effects 0.000 description 32
- 108091027544 Subgenomic mRNA Proteins 0.000 description 28
- 230000008685 targeting Effects 0.000 description 28
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 26
- 230000000295 complement effect Effects 0.000 description 26
- 102000053602 DNA Human genes 0.000 description 25
- 230000002068 genetic effect Effects 0.000 description 25
- 108091079001 CRISPR RNA Proteins 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 21
- 230000007423 decrease Effects 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 108091028113 Trans-activating crRNA Proteins 0.000 description 17
- 230000008859 change Effects 0.000 description 17
- 238000003197 gene knockdown Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 230000033616 DNA repair Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 108091027305 Heteroduplex Proteins 0.000 description 10
- 238000006116 polymerization reaction Methods 0.000 description 10
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 description 9
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 9
- 238000010362 genome editing Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 description 7
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 7
- 101710088570 Flagellar hook-associated protein 1 Proteins 0.000 description 7
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000007018 DNA scission Effects 0.000 description 6
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 6
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 102000004389 Ribonucleoproteins Human genes 0.000 description 6
- 108010081734 Ribonucleoproteins Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 108091032955 Bacterial small RNA Proteins 0.000 description 5
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 5
- 102100023823 Homeobox protein EMX1 Human genes 0.000 description 5
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 5
- 101001048956 Homo sapiens Homeobox protein EMX1 Proteins 0.000 description 5
- 101100166144 Staphylococcus aureus cas9 gene Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004900 c-terminal fragment Anatomy 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 108091092356 cellular DNA Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000005304 joining Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102100034452 Alternative prion protein Human genes 0.000 description 4
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 description 4
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000030648 nucleus localization Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101150037123 APOE gene Proteins 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 101710201453 DNA mismatch repair protein MLH1 Proteins 0.000 description 3
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 3
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 3
- 101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 3
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 3
- 102100036007 Ribonuclease 3 Human genes 0.000 description 3
- 101710192197 Ribonuclease 3 Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000037429 base substitution Effects 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 229940118537 p53 inhibitor Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000027412 CDKL5-deficiency disease Diseases 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 108010060248 DNA Ligase ATP Proteins 0.000 description 2
- 102100029995 DNA ligase 1 Human genes 0.000 description 2
- 108010055325 EphB3 Receptor Proteins 0.000 description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 2
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 description 2
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 108010015268 Integration Host Factors Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- 235000016976 Quercus macrolepis Nutrition 0.000 description 2
- 102000002490 Rad51 Recombinase Human genes 0.000 description 2
- 108010068097 Rad51 Recombinase Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 description 2
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000008970 bacterial immunity Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 1
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- BCZUPRDAAVVBSO-MJXNYTJMSA-N 4-acetylcytidine Chemical compound C1=CC(C(=O)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BCZUPRDAAVVBSO-MJXNYTJMSA-N 0.000 description 1
- UVGCZRPOXXYZKH-QADQDURISA-N 5-(carboxyhydroxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(O)C(O)=O)=C1 UVGCZRPOXXYZKH-QADQDURISA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- MMUBPEFMCTVKTR-IBNKKVAHSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-1h-pyrimidine-2,4-dione Chemical compound C=1NC(=O)NC(=O)C=1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O MMUBPEFMCTVKTR-IBNKKVAHSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 108060003760 HNH nuclease Proteins 0.000 description 1
- 102000029812 HNH nuclease Human genes 0.000 description 1
- 102100027489 Helicase-like transcription factor Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000577853 Homo sapiens DNA mismatch repair protein Mlh1 Proteins 0.000 description 1
- 101001081105 Homo sapiens Helicase-like transcription factor Proteins 0.000 description 1
- 101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 description 1
- 101000866795 Homo sapiens Non-histone chromosomal protein HMG-14 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 241000588654 Neisseria cinerea Species 0.000 description 1
- 102100031353 Non-histone chromosomal protein HMG-14 Human genes 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 241001386755 Parvibaculum lavamentivorans Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241001153986 Renicola lari Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000010856 establishment of protein localization Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 102000049917 human MLH1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 1
- 101150061338 mmr gene Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102220223999 rs1060502508 Human genes 0.000 description 1
- 102200030635 rs267608161 Human genes 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163136194P | 2021-01-11 | 2021-01-11 | |
US202163176180P | 2021-04-16 | 2021-04-16 | |
US202163176202P | 2021-04-16 | 2021-04-16 | |
US202163194865P | 2021-05-28 | 2021-05-28 | |
US202163194913P | 2021-05-28 | 2021-05-28 | |
US202163231230P | 2021-08-09 | 2021-08-09 | |
US202163255897P | 2021-10-14 | 2021-10-14 | |
PCT/US2022/012054 WO2022150790A2 (en) | 2021-01-11 | 2022-01-11 | Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4274894A2 true EP4274894A2 (de) | 2023-11-15 |
Family
ID=80119064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22702103.7A Pending EP4274894A2 (de) | 2021-01-11 | 2022-01-11 | Prime-editor-varianten, konstrukte und verfahren zur verbesserung der prime-editierungseffizienz und -präzision |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4274894A2 (de) |
JP (1) | JP2024503437A (de) |
AU (1) | AU2022206476A1 (de) |
CA (1) | CA3203876A1 (de) |
WO (1) | WO2022150790A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023096847A2 (en) * | 2021-11-24 | 2023-06-01 | Prime Medicine, Inc. | Methods and compositions for inhibiting mismatch repair |
US20240052370A1 (en) * | 2022-07-27 | 2024-02-15 | Inscripta, Inc. | Modulating cellular repair mechanisms for genomic editing |
WO2024077267A1 (en) | 2022-10-07 | 2024-04-11 | The Broad Institute, Inc. | Prime editing methods and compositions for treating triplet repeat disorders |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4663290A (en) | 1982-01-21 | 1987-05-05 | Molecular Genetics, Inc. | Production of reverse transcriptase |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US5374553A (en) | 1986-08-22 | 1994-12-20 | Hoffmann-La Roche Inc. | DNA encoding a thermostable nucleic acid polymerase enzyme from thermotoga maritima |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US5079352A (en) | 1986-08-22 | 1992-01-07 | Cetus Corporation | Purified thermostable enzyme |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5244797B1 (en) | 1988-01-13 | 1998-08-25 | Life Technologies Inc | Cloned genes encoding reverse transcriptase lacking rnase h activity |
US4965185A (en) | 1988-06-22 | 1990-10-23 | Grischenko Valentin I | Method for low-temperature preservation of embryos |
US5270179A (en) | 1989-08-10 | 1993-12-14 | Life Technologies, Inc. | Cloning and expression of T5 DNA polymerase reduced in 3'- to-5' exonuclease activity |
US5047342A (en) | 1989-08-10 | 1991-09-10 | Life Technologies, Inc. | Cloning and expression of T5 DNA polymerase |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
JP2709311B2 (ja) | 1990-09-28 | 1998-02-04 | エフ.ホフマン−ラ ロシュ アクチェンゲゼルシャフト | 熱安定性dnaポリメラーゼの5→3′のエキソヌクレアーゼ突然変異 |
EP0553264A4 (en) | 1990-10-05 | 1994-07-13 | Wayne M Barnes | Thermostable dna polymerase |
US5436149A (en) | 1993-02-19 | 1995-07-25 | Barnes; Wayne M. | Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension |
US5512462A (en) | 1994-02-25 | 1996-04-30 | Hoffmann-La Roche Inc. | Methods and reagents for the polymerase chain reaction amplification of long DNA sequences |
US5912155A (en) | 1994-09-30 | 1999-06-15 | Life Technologies, Inc. | Cloned DNA polymerases from Thermotoga neapolitana |
US5614365A (en) | 1994-10-17 | 1997-03-25 | President & Fellow Of Harvard College | DNA polymerase having modified nucleotide binding site for DNA sequencing |
US5773258A (en) | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
US6183998B1 (en) | 1998-05-29 | 2001-02-06 | Qiagen Gmbh Max-Volmer-Strasse 4 | Method for reversible modification of thermostable enzymes |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
GB9920194D0 (en) | 1999-08-27 | 1999-10-27 | Advanced Biotech Ltd | A heat-stable thermostable DNA polymerase for use in nucleic acid amplification |
AU785007B2 (en) | 1999-11-24 | 2006-08-24 | Mcs Micro Carrier Systems Gmbh | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
US8178291B2 (en) | 2005-02-18 | 2012-05-15 | Monogram Biosciences, Inc. | Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors |
US9783791B2 (en) | 2005-08-10 | 2017-10-10 | Agilent Technologies, Inc. | Mutant reverse transcriptase and methods of use |
EP2137300B1 (de) | 2007-04-26 | 2011-10-26 | Ramot at Tel-Aviv University Ltd. | Pluripotente autologe Stammzellen aus der mündlichen oder gastrointestinalen Schleimhaut |
CA3073384A1 (en) | 2008-09-05 | 2010-03-11 | President And Fellows Of Harvard College | Continuous directed evolution of proteins and nucleic acids |
EP3415621A1 (de) | 2009-03-04 | 2018-12-19 | Board Of Regents The University Of Texas System | Stabilisierte reverse-transkriptase-fusionsproteine |
US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
SG181601A1 (en) | 2009-12-10 | 2012-07-30 | Univ Minnesota | Tal effector-mediated dna modification |
WO2012054727A1 (en) | 2010-10-22 | 2012-04-26 | Bio-Rad Laboratories, Inc. | Reverse transcriptase mixtures with improved storage stability |
EP2655614B1 (de) | 2010-12-22 | 2017-03-15 | President and Fellows of Harvard College | Kontinuierliche gerichtete evolution |
AU2012314355B2 (en) | 2011-09-28 | 2018-01-18 | Zera Intein Protein Solutions, S.L. | Split inteins and uses thereof |
PL2877490T3 (pl) | 2012-06-27 | 2019-03-29 | The Trustees Of Princeton University | Inteiny podzielone, koniugaty i ich zastosowania |
US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
WO2014055778A2 (en) | 2012-10-03 | 2014-04-10 | Agrivida, Inc. | Multiprotein expression cassettes |
JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
WO2015134121A2 (en) | 2014-01-20 | 2015-09-11 | President And Fellows Of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
DK3212778T3 (da) | 2014-10-28 | 2019-11-04 | Agrivida Inc | Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser |
WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
US9580698B1 (en) | 2016-09-23 | 2017-02-28 | New England Biolabs, Inc. | Mutant reverse transcriptase |
JP2022518256A (ja) * | 2019-01-29 | 2022-03-14 | ユニバーシティ オブ ワシントン | 遺伝子編集の方法 |
US20220177877A1 (en) * | 2019-03-04 | 2022-06-09 | President And Fellows Of Harvard College | Highly multiplexed base editing |
JP2022526908A (ja) * | 2019-03-19 | 2022-05-27 | ザ ブロード インスティテュート,インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
-
2022
- 2022-01-11 JP JP2023542569A patent/JP2024503437A/ja active Pending
- 2022-01-11 EP EP22702103.7A patent/EP4274894A2/de active Pending
- 2022-01-11 WO PCT/US2022/012054 patent/WO2022150790A2/en active Application Filing
- 2022-01-11 AU AU2022206476A patent/AU2022206476A1/en active Pending
- 2022-01-11 CA CA3203876A patent/CA3203876A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022206476A1 (en) | 2023-07-20 |
WO2022150790A3 (en) | 2022-08-11 |
WO2022150790A2 (en) | 2022-07-14 |
JP2024503437A (ja) | 2024-01-25 |
CA3203876A1 (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11643652B2 (en) | Methods and compositions for prime editing nucleotide sequences | |
JP2023525304A (ja) | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 | |
US20230021641A1 (en) | Cas9 variants having non-canonical pam specificities and uses thereof | |
JP2023543803A (ja) | プライム編集ガイドrna、その組成物、及びその使用方法 | |
JPWO2020191233A5 (de) | ||
JPWO2020191234A5 (de) | ||
JPWO2020191243A5 (de) | ||
WO2022150790A2 (en) | Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision | |
WO2023076898A1 (en) | Methods and compositions for editing a genome with prime editing and a recombinase | |
WO2023015309A2 (en) | Improved prime editors and methods of use | |
CN117321201A (zh) | 用于增强引导编辑效率和精度的引导编辑器变体、构建体和方法 | |
WO2023205687A1 (en) | Improved prime editing methods and compositions | |
CN116685682A (zh) | 引导编辑向导rna、其组合物以及使用它们的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230717 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |